

# **Health of the Planet**

The planet faces an unprecedented challenge. While the focus at a global level has been on keeping global temperature change to below 1.5°C, the health of our planet is measured by a whole series of factors: biodiversity, pollution, water quality and availability, and the effects of extreme weather on supply chains and people's livelihoods. All of these are interrelated and have a direct impact on our health. All companies, including UCB, function as part of this ecosystem, and have a responsibility to respect the health of the planet.

For UCB, our commitment to health not only means for the patients we serve, our employees, and our partners, but also for communities, the wider public, and the planet.

#### UCB's Values

UCB is committed to building a healthier future. We strive to minimize the impact of our medicines on the environment while safeguarding access to medicines for the patients we serve. We are focused on pragmatic solutions and in making effective progress in areas where our business has the most impact.

We understand our impact goes beyond our own products and processes. Our efforts are not only aimed at changing on our own but also working with partners across our supply chain. We believe that transparency and public disclosure is one of the key steps to achieving sustainable change.

## UCB's Approach

UCB's corporate ambitions are used to develop customized environmental footprint targets for each department. Each department then has responsibility for implementing an associated roadmap to reduce their impact, contributing to our overarching ambition. We consider the green program as a core part of our culture, so that each crucial business decision UCB makes will be a green-conscious decision. We also extend our green values all the way through our supply chain.

UCB has signed key environmental initiatives such as the UN Global Compact and our C02e target is approved by the Science Based Target Initiative. We have disclosed our progress and results for water security and climate into the Carbon Disclosure Project since 2011 and independently audit our emissions. In 2022, we also started to disclose to the Task Force on Climate Related Disclosure.

#### Water

Our goal is to reduce our water withdrawal by 20% by 2030, compared with our 2015 base year. While our research and development pipeline involves several molecules which rely on waterintensive processes, we are dedicated to delivering on this target.

UCB's main manufacturing sites are implementing a long-term plan to decrease their water consumption following 3 successive steps:





- Monitoring: Good knowledge and understanding of consumption are needed to identify the relevant actions and most impactful projects
- Reducing: This is done by replacing existing equipment, processes, and behaviors with more eco-friendly equivalents
- Reuse Recycling: This involves the re-use of water for other activities that do not require the same level of quality, and the recycling of wastewater with additional treatments.

## **Reducing Waste**

We have set our target to reduce waste generation by 25% by 2030, compared with our 2015 base year.

Our waste mapping reinforces the need to reduce the amount of fresh raw materials used in chemical production. To deliver on our commitment, we pay close attention to the environmental impacts of chemical manufacturing. As our future pipeline is aiming toward more Bio products, the direct use of solvents should also be reduced in our business activities.

To reduce the environmental impact of our products through their lifecycle, we have launched a green product scorecard initiative. This aims at scoring our medicines' environmental performance based on systematic "cradle-to-grave" lifecycle analysis focusing on climate, water and waste impacts.

For every new synthetic molecule we produce, we follow three best practices to minimize waste generation:

- **Reduce**: Reducing fresh raw materials use
- Reuse: Directly reutilize raw materials multiple times
- **Recycle**: Treat the raw materials wastes either in-house or externally to make them reusable.

## Climate

Our current target aims to reduce our CO2e emission by 38% (scope 1, 2 and 3 excluding suppliers with a dedicated target) compared with our 2015 base year and that 60% of our suppliers will have science-based targets by 2025.

To achieve this, we are working simultaneously to:

- Reduce the impact of our existing footprint.
- Advocate for change management throughout the company.
- Limit the emissions coming from new projects through a green-by-design approach.
- Engage with suppliers to support their transition to a low carbon economy UCB has also committed that 60% of our suppliers will have science-based targets by 2025.
- Contribute to global carbon neutrality, beyond our value chain mitigation, by partnering with reforestation projects in Ethiopia and Congo



We embed green values in our supplier management activities through two distinct but complementary mechanisms: climate change mitigation and resilience toward climate change consequences. Resilience in our supply chain is critical so we can ensure patients have a reliable source of medicines.

In June 2023, UCB publicly realigned our climate target with the latest climate sciences by setting near- and long-term company-wide emission reduction targets in line with science-based net-zero through the Sciences Based Targets initiative (SBTi). We aim to validate our target by 2025.

Click **here** to find out more about UCB's environmental targets.